Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.4% – Here’s What Happened

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price rose 7.4% during trading on Thursday . The company traded as high as $20.29 and last traded at $20.3040. 644,411 shares traded hands during mid-day trading, a decline of 50% from the average session volume of 1,291,429 shares. The stock had previously closed at $18.91.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CAPR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 13th. Roth Capital reaffirmed a “buy” rating and set a $38.00 target price on shares of Capricor Therapeutics in a research report on Friday, May 15th. Finally, LADENBURG THALM/SH SH upgraded Capricor Therapeutics to a “strong-buy” rating in a report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $53.67.

Capricor Therapeutics Price Performance

The stock has a market capitalization of $1.16 billion, a P/E ratio of -8.71 and a beta of 0.42. The company has a 50 day simple moving average of $25.67 and a 200-day simple moving average of $27.58.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, equities analysts forecast that Capricor Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the transaction, the chief financial officer owned 8,223 shares of the company’s stock, valued at $260,669.10. The trade was a 75.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 50,000 shares of company stock valued at $1,551,658. 9.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. KBC Group NV purchased a new position in Capricor Therapeutics during the first quarter worth about $44,000. ACT Capital Management LLC bought a new stake in Capricor Therapeutics in the fourth quarter worth $43,000. Allworth Financial LP lifted its stake in shares of Capricor Therapeutics by 5,021.5% in the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 3,264 shares during the last quarter. State of Wyoming boosted its stake in shares of Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,913 shares during the period. Finally, Royal Bank of Canada boosted its position in Capricor Therapeutics by 12.4% during the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 557 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.